Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
POLEP286R neoantigen peptide is a tumor-specific neoantigen derived from a recurrent hotspot mutation (P286R) in the DNA polymerase epsilon (POLE) gene, which is frequently found in a subset of endometrial cancers characterized by an ultramutated phenotype. This peptide is specifically presented on the cell surface by HLA-A11:01 molecules. As a neoantigen, it is recognized as "non-self" by the immune system, making it a highly specific target for T-cell-based immunotherapies, such as peptide vaccines or TCR-engineered T-cell therapies. Research is currently focused on identifying high-affinity T-cell receptors (TCRs) that can recognize this peptide-HLA complex to induce a potent anti-tumor immune response in patients with POLE-mutant endometrial cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on POLEP286R neoantigen peptide.